• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

    35.44 +0.15 (+0.43%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 599,601
    Open 35.37
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 35.29
    Today's Range 35.37 - 35.64
    52wk Range 29.20 - 42.43
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
    Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
    Via Investor's Business Daily
    Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
    CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
    Via Talk Markets

    Performance

    YTD
    -2.50%
    -2.50%
    1 Month
    -9.57%
    -9.57%
    3 Month
    -14.46%
    -14.46%
    6 Month
    +11.48%
    +11.48%
    1 Year
    +6.27%
    +6.27%

    More News

    Read More
    Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
    Via Benzinga
    Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
    From Genentech
    Via Business Wire
    New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Biotech Momentum Trades For The Q4 Rally
    Via Talk Markets
    Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
    Via Investor's Business Daily
    Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
    Via Benzinga
    Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations
    Via Investor's Business Daily
    Can Roche Challenge Lilly and Novo in the Weight Loss Market?
    Via MarketBeat
    Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
    From Genentech
    Via Business Wire
    Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
    Via Investor's Business Daily
    Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
    Via Benzinga
    Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
    Via Investor's Business Daily
    Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
    From Genentech
    Via Business Wire
    Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
    Via Benzinga
    FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
    From Genentech
    Via Business Wire
    Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
    Via Benzinga
    Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
    Via Benzinga
    Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
    Via Benzinga
    Exposures Product Safety
    2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
    Via Benzinga
    Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million
    Via Talk Markets
    As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.